POPULATION SCREENING FOR CHRONIC DISEASE MAXIMISING BENEFITS, MINIMISING HARMS Public Health Association of Australia (PHAA) hold conference on current and future advances in population screening
With
Adjunct Professor Terry Slevin, Chief Executive Officer
Public Health Association of Australia
Australian Health Journal Segment
Filmed in Sydney | March 2025
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
There are established (and proposed) screening programs relevant to a range of diseases, notably breast, cervix, bowel cancer, and more recently for skin and lung cancer screening. There are a number of other chronic diseases where as new technologies are emerging and evidence is being gathered to support organised screening, (including but not limited to diabetes, CKD, MAFLD as well as cardiovascular and other risk assessment for primary prevention in general practice.
Population-based criteria for screening, based on WHO criteria and the Australian Population Based Screening Framework, aim to ensure that the benefits of screening outweigh and minimise any potential harms. These criteria are well understood by those involved in established screening programs and advocates for emerging screening programs are keen to learn from past experience how to compile evidence, design, implement and monitor programs, as well as ensure equitable participation. Similarly, there is much to learn from emerging programs and new technologies for those involved in established programs where adopting advances in evidence and technology can be challenging and perceived as slower.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
The conference provided opportunities for attendees to exchange information on population screening and learn from each other’s experience, across a range of disciplines. Those in attendance and presenting came from research, society, Government, program delivery, policy, consumers and clinicians.
Source: Adapted from Screening 2025 Conference website (PHAA operated)
-
Ensuring stringent quality standards in the lifecycle of medical devices
Dr Jasjit Baveja is the Associate Director of Policy at the Medical Technology Association of Australia (MTAA), where she oversees regulatory affairs, clinical code of practice, procurement, industry policy, reimbursement, and advocacy. With over 20 years of experience in the medical device regulatory space, Dr Bavej’s expertise lies in providing educational opportunities for regulatory professionals in Australia to ensure continuous learning and professional development. She collaborates closely with the Therapeutic Goods Administration (TGA) to run workshops that provide invaluable experience, networking opportunities, and skill enhancement.
-
Misinformation impacts routine vaccines
More significant changes in recent years have been health-related misinformation eroding trust in healthcare professionals, leading to people seeking alternative treatments or avoiding medical advice altogether. This can make it more difficult for healthcare professionals to provide effective treatment and care.
Recent vaccines delivered as part of the COVID-19 response, are having a consequential impact on the uptake of routine vaccines.
Australian Health Journal spoke with Dr Paul Griffin, an Infectious Diseases Physician and Microbiologist at Mater Health, and who has been involved in over 150 clinical trials in the field of infectious disease.
Paul talks about the importance of having reputable sources of information that can used to encourage people to understand what is involved in clinical trials and the roles of vaccines.
-
Occupational therapy creates profound impacts on client and patient lives
Margeaux Bartholomew-Carle is an Adelaide based registered Occupational Therapist and the Founder and CEO of Ardant.
Throughout her career, Margeaux has worked in various settings, including aged care, disability, assistive technology, prescription, and mental health. This diverse experience has deepened her understanding of the different needs among client groups.
